Please login to the form below

Not currently logged in
Email:
Password:

Vernalis Therapeutics appoints president and COO

Sandford Sommer brings experience from AstraZeneca

UK-based Vernalis Therapeutics has appointed Sandford Sommer as its new president and chief operating officer.

Ian Garland, chief executive of Vernalis, said: “We are delighted to welcome Sandy to Vernalis at this exciting time as we build our US commercial operations.

“Sandy's depth of experience in sales and marketing, as well as in general management, make him ideally qualified to lead our US operations through this critical period of multiple product launches and rapid growth.”

Sommer joins the development stage pharmaceutical company from AstraZeneca, where he has spent the past 24 years in a series of increasingly senior roles.

Most recently, Sommer served as country president for AstraZeneca's operations in Colombia and prior to that was global vice president, CNS.

He has also served on the board of the UK Columbia Trade organisation since March 2014.

Sommer said: “I am excited to be joining Vernalis at such an important time.

“I am looking forward to the opportunity to contribute to the growth of the company's US business and to help rapidly advance the company's promising pipeline.”

3rd May 2016

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics